Moreover, the therapeutic benefit of alectinib rechallenge after disease recurrence post-adjuvant therapy remains unclear.<h4>Case description</h4>We report the case of a 64-year-old woman diagnosed with stage pT3N2M0 IIIb ALK-positive lung adenocarcinoma. This evidence concerns the gene ALK and lung adenocarcinoma.